Skip to main content
. 2021 Aug 7;13(1):1955811. doi: 10.1080/19420862.2021.1955811

Figure 10.

Figure 10.

Relative abundance of HCPs identified in a drug candidate from different processes of development, FIH platform process (blue), intermediate process development (red), and commercially enabling process (green)